Try our beta test site
81 studies found for:    Lymphoma [CONDITION] AND Yttrium [ALL-FIELDS]
Show Display Options
Rank Status Study
1 Completed Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-Cell
Interventions: Drug: Yttrium-ibritumomab (Zevalin);   Drug: Rituximab
2 Completed Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
3 Completed Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
4 Unknown  Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
5 Active, not recruiting Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, and High-Dose Combination Chemotherapy Followed By Peripheral Blood Stem Cell Transplant in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: yttrium Y 90 ibritumomab tiuxetan
6 Active, not recruiting Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: yttrium Y 90 ibritumomab tiuxetan
7 Active, not recruiting Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Condition: Lymphoma
Interventions: Drug: Methylprednisolone;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Cisplatin;   Drug: Rituximab;   Drug: In-Zevalin;   Drug: Y-Zevalin
8 Active, not recruiting Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
9 Terminated Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Radiation: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Rituximab;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
10 Unknown  Zevalin® First Line in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab;   Drug: Rituximab
11 Completed Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
Condition: B-Cell Lymphoma
Intervention: Drug: Zevalin plus BEAM
12 Active, not recruiting Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: darbepoetin alfa;   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan
13 Terminated Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
Condition: Primary Central Nervous System Non-Hodgkin Lymphoma
Interventions: Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
14 Active, not recruiting
Has Results
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: Cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Biological: Yttrium-90 ibritumomab tiuxetan;   Biological: Indium-111 ibritumomab tiuxetan
15 Unknown  Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )
16 Unknown  Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Condition: Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: Rituxan;   Drug: motexafin gadolinium;   Drug: 111Indium-Zevalin and 90Yttrium-Zevalin
17 Completed Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Radiation: yttrium Y 90 ibritumomab tiuxetan;   Radiation: Indium 111 ibritumomab tiuxetan
18 Completed Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Condition: Lymphoma
Interventions: Drug: ibritumomab tiuxetan;   Drug: rituximab;   Drug: melphalan;   Drug: vinorelbine tartrate / G-CSF;   Procedure: autologous hematopoietic stem cell harvesting and transplantation
19 Active, not recruiting Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Conditions: Hodgkin Disease;   Hodgkin Lymphoma
Interventions: Procedure: Auto stem cell transplant;   Drug: BEAM;   Radiation: 111In-daclizumab;   Radiation: 90Y-daclizumab
20 Recruiting A Phase III Multicenter, Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Versus Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL)
Condition: Relapsed Follicular Lymphoma
Interventions: Other: ZEVALIN;   Drug: BEAM

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.